<p>Drucker Wealth 3.0 LLC 在最近向证券交易委员会（SEC）披露的报告中表示，在第二季度将其在艾伯维公司（NYSE:ABBV - 免费报告）的持股比例提高了 168.8%。该基金在此期间购买了额外的 2,817 股后，持有该公司 4,486 股股票。根据其最近向证券交易委员会（SEC）提交的文件，Drucker Wealth 3.0 LLC 在艾伯维的持股价值为 855,000 美元。</p>
<ul>
<li>为什么艾伯维和强生可能会超越辉瑞</li>
</ul>
<p>其他几家机构投资者也增加或减少了在该公司的股份。Nuveen LLC 在第一季度购买了艾伯维的新股份，价值为 18.19154 亿美元。Assenagon Asset Management S.A. 在第二季度将其在艾伯维的持股提高了 550.9%。Assenagon Asset Management S.A. 现在拥有 4,332,054 股该公司的股票，价值为 8.04116 亿美元，此前在上个季度又收购了 3,666,521 股。高盛集团在第一季度将其在艾伯维的持股提高了 31.6%。高盛集团现在拥有 14,646,908 股该公司的股票，价值为 30.68820 亿美元，此前在上个季度又收购了 3,519,187 股。Kingstone Capital Partners Texas LLC 在第二季度购买了艾伯维的新股份，价值约为 5.81817 亿美元。最后，贝斯默集团在第一季度将其在艾伯维的持股提高了 147.6%。贝斯默集团现在拥有 2,752,953 股该公司的股票，价值为 5.76800 亿美元，此前在上个季度又购买了 1,641,091 股。机构投资者持有该公司 70.23% 的股票。</p>
<h2>艾伯维价格表现</h2>
<p>艾伯维周五开盘价为 230.88 美元。该公司的市值为 4,078.6 亿美元，市盈率为 109.94，PEG 比率为 1.35，贝塔值为 0.51。艾伯维公司的 12 个月最低价为 163.81 美元，12 个月最高价为 244.81 美元。该公司的流动比率为 0.74，速动比率为 0.61，债务股本比率为 44.14。该股票的 50 日移动平均价格为 214.84 美元，200 日移动平均价格为 196.79 美元。</p>
<ul>
<li>3 只卓越股票以建立长期财富</li>
</ul>
<p>艾伯维（NYSE:ABBV - 获取免费报告）最近于 7 月 31 日（星期四）发布了其财报。该公司报告本季度每股收益（EPS）为 2.97 美元，低于分析师一致预期的 3.24 美元，差距为 0.27 美元。该季度的营业收入为 154.2 亿美元，而分析师预期为 149.3 亿美元。艾伯维的股本回报率为 699.66%，净利润率为 6.45%。与去年同期相比，艾伯维的季度收入增长了 6.6%。去年同期，该公司每股收益为 2.65 美元。作为一个整体，卖方分析师预计艾伯维公司今年将发布 12.31 美元的每股收益。</p>
<h2>艾伯维股息公告</h2>
<p>该公司最近还宣布了一项季度股息，将于 11 月 14 日（星期五）支付。10 月 15 日（星期三）登记在册的股东将获得 1.64 美元的股息。该股息的除息日期为 10 月 15 日（星期三）。这相当于年化 6.56 美元的股息，收益率为 2.8%。艾伯维的股息支付比率（DPR）目前为 312.38%。</p>
<h2>艾伯维内部交易</h2>
<ul>
<li>随着市场轮动，这只医疗 ETF 引领潮流</li>
</ul>
<p>在其他新闻中，执行副总裁 Azita Saleki-Gerhardt 于 8 月 12 日（星期二）出售了 42,370 股公司的股票。股票以 198.42 美元的平均价格出售，总价值为 8,407,055.40 美元。出售后，该执行副总裁直接持有 177,292 股公司股票，价值约为 35,178,278.64 美元。这笔交易代表其持股减少了 19.29%。该出售在向证券交易委员会提交的文件中披露，可以通过此链接访问。此外，执行副总裁 Nicholas Donoghoe 于 8 月 5 日（星期二）出售了 13,295 股公司的股票。股票以 198.51 美元的平均价格出售，总价值为 2,639,190.45 美元。出售完成后，该执行副总裁持有 58,247 股公司股票，价值约为 11,562,611.97 美元。这代表其持股减少了 18.58%。该出售的披露信息可以在这里找到。公司内部人士持有 0.25% 的股票。</p>
<h2>分析师评级变动</h2>
<p>几位研究分析师最近对该公司发表了评论。汇丰全球研究在 10 月 1 日（星期三）的研究报告中将艾伯维的评级从 “强力买入” 下调至 “持有”。Cantor Fitzgerald 在研究报告中对艾伯维设定了 250.00 美元的目标价，并给予该股票 “增持” 评级。大和资本市场在 8 月 7 日（星期四）的报告中将艾伯维的评级从 “中性” 上调至 “跑赢大盘”，并设定了 214.00 美元的目标价。古根海姆在 8 月 1 日（星期五）的研究报告中将艾伯维的目标价从 216.00 美元上调至 227.00 美元，并给予该公司 “买入” 评级。最后，摩根士丹利在 8 月 1 日（星期五）的报告中将艾伯维的目标价从 250.00 美元上调至 255.00 美元，并给予该公司 “增持” 评级。目前，三位投资分析师对该股票给予 “强力买入” 评级，十六位给予 “买入” 评级，九位给予 “持有” 评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “适度买入”，平均目标价为 231.90 美元。</p>
<p><strong>查看我们最新的艾伯维股票分析</strong></p>
<h2>关于艾伯维</h2>
<p>（免费报告）</p>
<p>艾伯维公司在全球范围内发现、开发、生产和销售药品。该公司提供的药品包括：Humira，用于治疗自身免疫性疾病和肠道贝赫切特病以及脓皮病；Skyrizi，用于治疗中度至重度斑块型银屑病、银屑病性疾病和克罗恩病；Rinvoq，用于治疗类风湿性关节炎、银屑病性关节炎、强直性脊柱炎、特应性皮炎、轴性脊柱关节炎、溃疡性结肠炎和克罗恩病；Imbruvica，用于治疗成人血癌患者；Epkinly，用于治疗淋巴瘤；Elahere，用于治疗癌症；以及 Venclexta/Venclyxto，用于治疗血癌。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，优于艾伯维</li>
<li>3 只证明仍然必不可少的食品杂货股票</li>
<li>3 只被重仓做空的股票，可能在降息时反弹</li>
<li>股票分析师评级和加拿大分析师评级</li>
<li>博通获得第二个 420 美元目标价，CPO 胜利提升前景</li>
<li>专家股票交易心理学技巧</li>
<li>百事可乐的深度折扣将很快消失：趁现在买入</li>
</ul>
<p><strong>想看看其他对 ABBV 感兴趣的对冲基金持有哪些股票吗？</strong> 请访问 HoldingsChannel.com，获取艾伯维公司（NYSE:ABBV - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在艾伯维吗？</h2>
<p>在考虑艾伯维之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而艾伯维并不在名单上。</p>
<p>虽然艾伯维目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

艾伯维

<p>Drucker Wealth 3.0 LLC 在第二季度将其在艾伯维（AbbVie Inc.，纽约证券交易所代码：ABBV）的持股增加了 168.8%，额外购买了 2,817 股，使其总持股达到 4,486 股，价值为 855,000 美元。其他机构投资者也增加了他们的持股，其中 Nuveen LLC 和 Assenagon Asset Management 的增幅尤为显著。艾伯维最近公布了第二季度每股收益为 2.97 美元，低于预期，但收入同比增长了 6.6%。该公司宣布季度股息为 1.64 美元，将于 2023 年 11 月 14 日支付，收益率为 2.8%</p>

<p>Drucker Wealth 3.0 LLC boosted its position in AbbVie Inc. (NYSE:ABBV - Free Report) by 168.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,486 shares of the company's stock after purchasing an additional 2,817 shares during the period. Drucker Wealth 3.0 LLC's holdings in AbbVie were worth $855,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p>
<div class="lb-trans"><p>Drucker Wealth 3.0 LLC 在最近向证券交易委员会（SEC）披露的报告中表示，在第二季度将其在艾伯维公司（NYSE:ABBV - 免费报告）的持股比例提高了 168.8%。该基金在此期间购买了额外的 2,817 股后，持有该公司 4,486 股股票。根据其最近向证券交易委员会（SEC）提交的文件，Drucker Wealth 3.0 LLC 在艾伯维的持股价值为 855,000 美元。</p>
</div><ul>
<li>Why AbbVie and Johnson &amp; Johnson Could Outperform Pfizer</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么艾伯维和强生可能会超越辉瑞</li>
</ul>
</div><p>Several other institutional investors have also added to or reduced their stakes in the company. Nuveen LLC bought a new stake in shares of AbbVie during the first quarter worth $1,819,154,000. Assenagon Asset Management S.A. raised its holdings in shares of AbbVie by 550.9% in the second quarter. Assenagon Asset Management S.A. now owns 4,332,054 shares of the company's stock valued at $804,116,000 after acquiring an additional 3,666,521 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of AbbVie by 31.6% in the first quarter. Goldman Sachs Group Inc. now owns 14,646,908 shares of the company's stock valued at $3,068,820,000 after acquiring an additional 3,519,187 shares in the last quarter. Kingstone Capital Partners Texas LLC bought a new stake in shares of AbbVie in the second quarter valued at about $581,817,000. Finally, Bessemer Group Inc. raised its holdings in shares of AbbVie by 147.6% in the 1st quarter. Bessemer Group Inc. now owns 2,752,953 shares of the company's stock valued at $576,800,000 after purchasing an additional 1,641,091 shares in the last quarter. Institutional investors own 70.23% of the company's stock.</p>
<div class="lb-trans"><p>其他几家机构投资者也增加或减少了在该公司的股份。Nuveen LLC 在第一季度购买了艾伯维的新股份，价值为 18.19154 亿美元。Assenagon Asset Management S.A. 在第二季度将其在艾伯维的持股提高了 550.9%。Assenagon Asset Management S.A. 现在拥有 4,332,054 股该公司的股票，价值为 8.04116 亿美元，此前在上个季度又收购了 3,666,521 股。高盛集团在第一季度将其在艾伯维的持股提高了 31.6%。高盛集团现在拥有 14,646,908 股该公司的股票，价值为 30.68820 亿美元，此前在上个季度又收购了 3,519,187 股。Kingstone Capital Partners Texas LLC 在第二季度购买了艾伯维的新股份，价值约为 5.81817 亿美元。最后，贝斯默集团在第一季度将其在艾伯维的持股提高了 147.6%。贝斯默集团现在拥有 2,752,953 股该公司的股票，价值为 5.76800 亿美元，此前在上个季度又购买了 1,641,091 股。机构投资者持有该公司 70.23% 的股票。</p>
</div><h2>AbbVie Price Performance</h2>
<div class="lb-trans"><h2>艾伯维价格表现</h2>
</div><p>ABBV opened at $230.88 on Friday. The firm has a market cap of $407.86 billion, a price-to-earnings ratio of 109.94, a PEG ratio of 1.35 and a beta of 0.51. AbbVie Inc. has a 12-month low of $163.81 and a 12-month high of $244.81. The company has a current ratio of 0.74, a quick ratio of 0.61 and a debt-to-equity ratio of 44.14. The stock's 50-day moving average price is $214.84 and its 200 day moving average price is $196.79.</p>
<div class="lb-trans"><p>艾伯维周五开盘价为 230.88 美元。该公司的市值为 4,078.6 亿美元，市盈率为 109.94，PEG 比率为 1.35，贝塔值为 0.51。艾伯维公司的 12 个月最低价为 163.81 美元，12 个月最高价为 244.81 美元。该公司的流动比率为 0.74，速动比率为 0.61，债务股本比率为 44.14。该股票的 50 日移动平均价格为 214.84 美元，200 日移动平均价格为 196.79 美元。</p>
</div><ul>
<li>3 Exceptional Stocks to Build Long-Term Wealth</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只卓越股票以建立长期财富</li>
</ul>
</div><p>AbbVie (NYSE:ABBV - Get Free Report) last released its earnings results on Thursday, July 31st. The company reported $2.97 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.24 by ($0.27). The business had revenue of $15.42 billion for the quarter, compared to analyst estimates of $14.93 billion. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.AbbVie's quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter last year, the company earned $2.65 earnings per share. As a group, sell-side analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current year.</p>
<div class="lb-trans"><p>艾伯维（NYSE:ABBV - 获取免费报告）最近于 7 月 31 日（星期四）发布了其财报。该公司报告本季度每股收益（EPS）为 2.97 美元，低于分析师一致预期的 3.24 美元，差距为 0.27 美元。该季度的营业收入为 154.2 亿美元，而分析师预期为 149.3 亿美元。艾伯维的股本回报率为 699.66%，净利润率为 6.45%。与去年同期相比，艾伯维的季度收入增长了 6.6%。去年同期，该公司每股收益为 2.65 美元。作为一个整体，卖方分析师预计艾伯维公司今年将发布 12.31 美元的每股收益。</p>
</div><h2>AbbVie Dividend Announcement</h2>
<div class="lb-trans"><h2>艾伯维股息公告</h2>
</div><p>The business also recently declared a quarterly dividend, which will be paid on Friday, November 14th. Shareholders of record on Wednesday, October 15th will be given a $1.64 dividend. The ex-dividend date of this dividend is Wednesday, October 15th. This represents a $6.56 dividend on an annualized basis and a yield of 2.8%. AbbVie's dividend payout ratio (DPR) is currently 312.38%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度股息，将于 11 月 14 日（星期五）支付。10 月 15 日（星期三）登记在册的股东将获得 1.64 美元的股息。该股息的除息日期为 10 月 15 日（星期三）。这相当于年化 6.56 美元的股息，收益率为 2.8%。艾伯维的股息支付比率（DPR）目前为 312.38%。</p>
</div><h2>Insider Transactions at AbbVie</h2>
<div class="lb-trans"><h2>艾伯维内部交易</h2>
</div><ul>
<li>As the Market Rotates, This Healthcare ETF Is Leading the Way</li>
</ul>
<div class="lb-trans"><ul>
<li>随着市场轮动，这只医疗 ETF 引领潮流</li>
</ul>
</div><p>In other news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the firm's stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $198.42, for a total value of $8,407,055.40. Following the sale, the executive vice president directly owned 177,292 shares in the company, valued at approximately $35,178,278.64. This trade represents a 19.29% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this link. Also, EVP Nicholas Donoghoe sold 13,295 shares of the firm's stock in a transaction on Tuesday, August 5th. The shares were sold at an average price of $198.51, for a total value of $2,639,190.45. Following the completion of the sale, the executive vice president owned 58,247 shares in the company, valued at approximately $11,562,611.97. This represents a 18.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.25% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在其他新闻中，执行副总裁 Azita Saleki-Gerhardt 于 8 月 12 日（星期二）出售了 42,370 股公司的股票。股票以 198.42 美元的平均价格出售，总价值为 8,407,055.40 美元。出售后，该执行副总裁直接持有 177,292 股公司股票，价值约为 35,178,278.64 美元。这笔交易代表其持股减少了 19.29%。该出售在向证券交易委员会提交的文件中披露，可以通过此链接访问。此外，执行副总裁 Nicholas Donoghoe 于 8 月 5 日（星期二）出售了 13,295 股公司的股票。股票以 198.51 美元的平均价格出售，总价值为 2,639,190.45 美元。出售完成后，该执行副总裁持有 58,247 股公司股票，价值约为 11,562,611.97 美元。这代表其持股减少了 18.58%。该出售的披露信息可以在这里找到。公司内部人士持有 0.25% 的股票。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Several research analysts have recently commented on the company. Hsbc Global Res lowered AbbVie from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Wednesday, October 1st. Cantor Fitzgerald set a $250.00 price target on AbbVie and gave the stock an &#34;overweight&#34; rating in a research report on Thursday. Daiwa Capital Markets upgraded shares of AbbVie from a &#34;neutral&#34; rating to an &#34;outperform&#34; rating and set a $214.00 price objective on the stock in a report on Thursday, August 7th. Guggenheim upped their price target on shares of AbbVie from $216.00 to $227.00 and gave the company a &#34;buy&#34; rating in a research note on Friday, August 1st. Finally, Morgan Stanley increased their price objective on AbbVie from $250.00 to $255.00 and gave the company an &#34;overweight&#34; rating in a report on Friday, August 1st. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $231.90.</p>
<div class="lb-trans"><p>几位研究分析师最近对该公司发表了评论。汇丰全球研究在 10 月 1 日（星期三）的研究报告中将艾伯维的评级从 “强力买入” 下调至 “持有”。Cantor Fitzgerald 在研究报告中对艾伯维设定了 250.00 美元的目标价，并给予该股票 “增持” 评级。大和资本市场在 8 月 7 日（星期四）的报告中将艾伯维的评级从 “中性” 上调至 “跑赢大盘”，并设定了 214.00 美元的目标价。古根海姆在 8 月 1 日（星期五）的研究报告中将艾伯维的目标价从 216.00 美元上调至 227.00 美元，并给予该公司 “买入” 评级。最后，摩根士丹利在 8 月 1 日（星期五）的报告中将艾伯维的目标价从 250.00 美元上调至 255.00 美元，并给予该公司 “增持” 评级。目前，三位投资分析师对该股票给予 “强力买入” 评级，十六位给予 “买入” 评级，九位给予 “持有” 评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “适度买入”，平均目标价为 231.90 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on AbbVie</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的艾伯维股票分析</strong></p>
</div><h2>About AbbVie</h2>
<div class="lb-trans"><h2>关于艾伯维</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.</p>
<div class="lb-trans"><p>艾伯维公司在全球范围内发现、开发、生产和销售药品。该公司提供的药品包括：Humira，用于治疗自身免疫性疾病和肠道贝赫切特病以及脓皮病；Skyrizi，用于治疗中度至重度斑块型银屑病、银屑病性疾病和克罗恩病；Rinvoq，用于治疗类风湿性关节炎、银屑病性关节炎、强直性脊柱炎、特应性皮炎、轴性脊柱关节炎、溃疡性结肠炎和克罗恩病；Imbruvica，用于治疗成人血癌患者；Epkinly，用于治疗淋巴瘤；Elahere，用于治疗癌症；以及 Venclexta/Venclyxto，用于治疗血癌。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than AbbVie</li>
<li>3 Grocery Stocks That Are Proving They Are Still Essential</li>
<li>3 Heavily Shorted Stocks That Could Pop on Rate Cuts</li>
<li>Stock Analyst Ratings and Canadian Analyst Ratings</li>
<li>Broadcom Gets Second $420 Target as CPO Win Boosts Outlook</li>
<li>Expert Stock Trading Psychology Tips</li>
<li>PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，优于艾伯维</li>
<li>3 只证明仍然必不可少的食品杂货股票</li>
<li>3 只被重仓做空的股票，可能在降息时反弹</li>
<li>股票分析师评级和加拿大分析师评级</li>
<li>博通获得第二个 420 美元目标价，CPO 胜利提升前景</li>
<li>专家股票交易心理学技巧</li>
<li>百事可乐的深度折扣将很快消失：趁现在买入</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ABBV?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 ABBV 感兴趣的对冲基金持有哪些股票吗？</strong> 请访问 HoldingsChannel.com，获取艾伯维公司（NYSE:ABBV - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ABBV"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in AbbVie Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在艾伯维吗？</h2>
</div><p>Before you consider AbbVie, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑艾伯维之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而艾伯维并不在名单上。</p>
</div><p>While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然艾伯维目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Drucker Wealth 3.0 LLC 购买了 2,817 股艾伯维公司（AbbVie Inc.）的股票，代码为$ABBV